Thomas Carlsen is CEO of the Novo Nordisk Foundation Cellerator P/S, which was established in 2023 with the mission to accelerate the development of cell-based therapies into clinical trials, and to establish a new key unit in the cell therapy ecosystem. Thomas has held the position since February 2023.

Thomas has held several positions in Novo Nordisk A/S, including Department Manager in the department of Virology from 2016 to 2018, and more recently, between 2018 and 2022 as Director for Cell Therapy Process Development, based in Copenhagen and in Tokyo. Thomas was deployed to Tokyo to work for Novo Nordisk A/S business partners, Heartseed. 

Thomas holds an MSc in Human Biology (2009), from the University of Copenhagen and a PhD in Virology (2013) under the Copenhagen Hepatitis C program, University of Copenhagen, where he had a research visit to Ghent University.